1.Hepatitis B surface antigen serum titer: Correlation with hepatitis B virus DNA and alanine aminotransferase levels among hepatitis B e Antigen-negative chronic hepatitis B patients.
Sy Mark Lester S. ; Jamias Jade D.
Philippine Journal of Internal Medicine 2015;53(3):1-6
BACKGROUND AND AIMS: The precise identification of true inactive hepatitis B carrier is difficult due to frequent fluctuations in Hepatitis B virus (HBV) DNA and serum transaminase levels, needing serial determinations for a period of at least one year. Hence we correlated the hepatitis B surface antigen (HBs Ag) titer of untreated Hepatitis B e Antigen (HBe Ag)-negative patients with their corresponding HBV DNA and alanine aminotransferase (ALT) levels, classified these patients as either inactive carrier or patients in the reactivation phase using the American Association for the Study of Liver Diseases (AASLD) guidelines and finally determined if there was a significant difference in HBs Ag titer between these groups.
METHODS: A cross sectional retrospective study was done. All HBe Ag- negative Chronic hepatitis B (CHB) patients who had their HBs Ag titer, HBV DNA and ALT done at National Kidney and Transplant Institute (NKTI) were obtained and clinical information was abstracted from their case records. A total of 40 patients were included in the study.
RESULTS: The mean HBs Ag titer among untreated HBe Ag negative CHB patients was 3037.04 IU/mL (SD +/- 8718.94 IU/mL). Using Spearman's coefficient of correlation, HBs Ag was found to be directly correlated with HBV DNA (R = 0.821, p = 0 < 0.05) and serum ALT (R = 0.654, p = 0 < 0.05). Moreover, using Mann Whitney T Test, the mean difference in HBs Ag titer between inactive carrier group (mean 103.72 IU/mL, SD +/- 144.25) and reactivation phase group (mean 5690.99 IU/mL, SD +/- 11517.39) was significant (p value = 0 < 0.05).
CONCLUSION: HBs Ag titer was found to be directly correlated with HBV DNA and ALT. To our knowledge, this is the first local study done that supports the concept that HBs Ag titer can provide complementary information in differentiating patient as true inactive carrier from those in the reactivation phase.
Human ; Male ; Female ; Middle Aged ; Adult ; Hepatitis B Surface Antigens ; Hepatitis B, Chronic ; Alanine Transaminase ; Hepatitis B Virus ; Dna, Viral ; Serum
2.The 2014 Hepatology Society of the Philippines consensus statements on the diagnosis and treatment of hepatitis C.
Wong Stephen N. ; Campos Jane R. ; Cua Ian Homer Y. ; Jamias Jade D. ; Labio Madalinee Eternity D. ; Tan Judy L. ; Ong Janus P. ; Salavaña Angela D. ; Go Arlinking O. ; Payawal Diana A
Philippine Journal of Internal Medicine 2015;53(1):1-14
Hepatitis C virus (HCV) infection is a devastating disease that is increasingly being diagnosed among Filipinos, especially in at-risk populations. There are disease-specific nuances in the evaluation and management of this infection. Furthermore, advances in the field brought about by clinical research are rapidly moulding the way we evaluate and manage HCV patients. Evidently, consensus statements formulated by experts in the field are needed in order to serve as a guide to physicians who see HCV patients in the clinic. With this in mind, the Hepatology Society of the Philippines spearheaded the formation of these statements which aimed to address issues in the diagnosis, evaluation, treatment, and follow-up care of patients with HCV infection.
Recommendations on the specific tests to perform in the evaluation of HCV patients before, during and after treatment, and first-line treatment of patients with acute and chronic HCV infection were provided. Treatment algorithms for chronic HCV infection, divided according to viral genotype, were also devised. We acknowledge the limitations brought about by the local inavailability of some drugs/treatment regimens in the local setting at the time of the formulation of these statements. As such, these statements will be revised as soon as new data become locally applicable.
Hepatitis C ; Diagnosis ; Infection ; Consensus ; Carcinoma, Hepatocellular ; Liver Cirrhosis
3.The 2014 Hepatology Society of the Philippines consensus statements on the management of chronic hepatitis B.
Jamias Jade D. ; Balce-Santos Dulcinea A. ; Bocobo Joseph C. ; Labio Madalinee Eternity D. ; Lontok Ma. Antoinette DC. ; Macatula Therese C. ; Ong Janus P. ; Ong-Go Arlinking K. ; Wong Stephen ; Yu Ira I. ; Payawal Diana A.
Philippine Journal of Internal Medicine 2015;53(1):17-33
Chorinic hepatitis B virus (CHB) infection is a serious problem that affects over 300 million people worldwide and is highly prevalent in the Asia Pacific region. In the Philippines an estimate 7.3 million Filipinos or 16.7% of adults are chronically infected with HBV, more than twice the average prevalence in the Western Pacific region.
In view of the above, the Hepatology Society of the Philippines (HSP) embarked on the development of consensus statements on the management of hepatitis B with the primary objectives of standardizing approach to management, empowering other physicians involved in the management of hepatitis B and advancing treatment subsidy by the Philippine Health Insurance Corporation (PhilHealth).
The local guidelines include screening and vaccination general management, indications for assessment of fibrosis in those who did not meet treatment criteria. indications for treatment, on-treatment and post-treatment monitoring and duration of antiviral treatment. Recommendations on the management of antiviral drug resistance, management of special populations including patients with concurrent HIV or hepatitis C infection, women of child-bearing age (pregnancy and breastfeeding), patients with decompensated liver disease, patients receiving immunosuppressive medications or chemotherapy and patients in the setting of hepatocellular carcinoma are also included. However, the guidelines did not include management for patients with liver and other solid organ transplantation, patients on renal replacement therapy, and children.
The consensus statements will be amended accordingly as new therapies become available.
Hepatitis B ; Consensus ; Hepatitis B, Chronic ; Hepatitis B Virus ; Fibrosis ; Drug Therapy ; Carcinoma, Hepatocellular ; Liver Cirrhosis ; Hepatitis Delta Virus ; Hiv
4.Predictors of mortality among end-stage renal disease patients with COVID-19 admitted in a Philippine Tertiary Government Hospital: A retrospective cohort study
Saul B. Suaybaguio ; Jade D. Jamias ; Marla Vina A. Briones
Acta Medica Philippina 2024;58(Early Access 2024):1-8
Background and Objective:
Several studies have examined the predictors of mortality among COVID-19-infected
patients; however, to date, few published studies focused on end-stage renal disease patients. The present study,therefore, aims to determine the predictors of in-hospital mortality among end-stage renal disease patients with COVID-19 admitted to a Philippine tertiary hospital.
Methods:
The researcher utilized a retrospective cohort design. A total of 449 adult end-stage renal disease patients on renal replacement therapy diagnosed with moderate-to-severe COVID-19 and were admitted at the National Kidney and Transplant Institute from June 2020 to 2021 were included. Logistic regression analysis was used to determine the factors associated with in-hospital mortality.
Results:
In-hospital mortality among end-stage renal disease patients with COVID-19 was 31.18% (95% CI: 26.92-
35.69%). Older age (OR=1.03), male sex (OR=0.56), diabetes mellitus (OR=1.80), coronary artery disease (OR=1.71), encephalopathy (OR=7.58), and intubation (OR=30.78) were associated with in-hospital mortality.
Conclusion
Patients with ESRD and COVID-19 showed a high in-hospital mortality rate. Older age, diabetes mellitus, coronary artery disease, encephalopathy, and intubation increased the odds of mortality. Meanwhile, males had lower odds of mortality than females.
COVID-19
;
Kidney Failure, Chronic
;
Hospital Mortality
;
Renal Replacement Therapy
5.Gastrointestinal manifestation and in-hospital mortality among end-stage renal disease patients with COVID-19: A single-center retrospective cohort study
Saul B. Suaybaguio ; Jade D. Jamias ; Marla Vina A. Briones
Acta Medica Philippina 2024;58(Early Access 2024):1-7
Background and Objective:
Gastrointestinal (GI) manifestations among COVID-19 patients are common; however, their relation with patient outcomes remains unclear. The study, therefore, aims to determine the association of GI manifestation with in-hospital mortality among end-stage renal disease patients (ESRD).
Methods:
This is a retrospective cohort design. All 501 ESRD patients with COVID-19 and admitted to the National Kidney and Transplant Institute from June 2020 to 2021 were included. GI manifestation was defined as the presence of any of the following signs and symptoms on admission: dysgeusia, anorexia, abdominal pain, nausea, vomiting, diarrhea, and jaundice. The outcome of interest was in hospital mortality, defined as death due to any cause during hospital stay. Stata17 was used for data analysis.
Results:
The overall prevalence of GI manifestation was 58.08% (95% CI: 53.63-62.45). The most common symptoms were abdominal pain (27.15%), loss of appetite (24.35%), and nausea (19.76%). Patients with GI manifestation had a higher proportion of stroke, lower median systolic blood pressure, and a lower proportion of abnormal oxygen saturation and diastolic blood pressure than those without GI manifestation. Across all clinical outcomes, only hospital stay significantly differ between those with and without GI manifestation. In-hospital mortality was 31.14% (95% CI: 27.10-35.39%) and showed no significant association with GI manifestation (OR= 0.94, p=0.749).
Conclusions
GI manifestation was common among ESRD patients with moderate-to-severe COVID-19. The inhospital mortality rate is also high; however, GI manifestation was not associated with this outcome. Meanwhile, GI manifestation leads to longer hospital stay.
Kidney Diseases
;
SARS-CoV-2
7.Guidelines for liver transplantation during the COVID pandemic in the Philippines: Joint statement of the Philippine Association of Hepato-Pancreato-Biliary Surgeons (PAHPBS) and the Hepatology Society of the Philippines (HSP), 08 December 2020.
Maria Vanessa H. De Villa ; Mara Teresa T. Panlilio ; Amornetta P. Jordan-Casupang ; Ian Homer Y. Cua ; Anthony Q. Yap ; Jade D. Jamias ; Marco M. Sumo ; Wendell Z. Espinosa ; Noruel Gerard A. Salvador ; Jennielyn C. Agcaoili-Conde ; Aldwin D. Ong ; Catherine SC Teh ; Roberto N. De Guzman
Philippine Journal of Surgical Specialties 2020;75(2):155-157